BCM
PLRX icon

Bayesian Capital Management’s Pliant Therapeutics PLRX Stock Holding History

Bayesian Capital Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,000
Closed -$208K – 976
2023
Q3 		$208K Buy
+12,000
New +$208K 0.02% 546

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Bayesian Capital Management's PLRX Position: Q4 2023 in Review

Bayesian Capital Management sold out of Pliant Therapeutics (PLRX) in Q4 2023, closing a stake of 12,000 shares — an estimated $208K sold.

Bayesian Capital Management first reported a position in PLRX in Q3 2023 and held it in 1 quarter. The position peaked at $208K in Q3 2023. 134 funds tracked by Wall St. Rank hold PLRX as of Q4 2023.

  • Bayesian Capital Management reported no remaining Pliant Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Bayesian Capital Management sold 12,000 Pliant Therapeutics shares in Q4 2023, an estimated $208K.
  • Bayesian Capital Management first reported a position in Pliant Therapeutics in Q3 2023 and held it in 1 quarter.
  • Bayesian Capital Management's Pliant Therapeutics position peaked at $208K in Q3 2023.
  • 134 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.